Related Experiment Video
Updated: Jun 30, 2025

A Portal Vein Injection Model to Study Liver Metastasis of Breast Cancer
Published on: December 26, 2016
Novel furan chalcone modulates PHD-2 induction to impart antineoplastic effect in mammary gland carcinoma
Shubham Rastogi1, Mohd Nazam Ansari2, Abdulaziz S Saeedan2
1Department of Pharmaceutical Sciences, School of Biomedical and Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow, Uttar Pradesh, India.
Abstract:
Normoxic inactivation of prolyl hydroxylase-2 (PHD-2) in tumour microenvironment paves the way for cancer cells to thrive under the influence of HIF-1α and NF-κB. Henceforth, the present study is aimed to identify small molecule activators of PHD-2. A virtual screening was conducted on a library consisting of 265,242 chemical compounds, with the objective of identifying molecules that exhibit structural similarities to the furan chalcone scaffold. Further, PHD-2 activation potential of screened compound was determined using in vitro 2-oxoglutarate assay. The cytotoxic activity and apoptotic potential of screened compound was determined using various staining techniques, including 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide, 4',6-diamidino-2-phenylindole (DAPI), 1,1',3,3'-tetraethylbenzimi-dazolylcarbocyanine iodide (JC-1), and acridine orange/ethidium bromide (AO/EB), against MCF-7 cells. 7,12-Dimethylbenz[a]anthracene (DMBA) model of mammary gland cancer was used to study the in vivo antineoplastic efficacy of screened compound. [(E)-1-(4-fluorophenyl)-3-(furan-2-yl) prop-2-en-1-one] (BBAP-7) was screened and validated as a PHD-2 activator by an in vitro 2-oxo-glutarate assay. The IC50 of BBAP-7 on MCF-7 cells is 18.84 µM. AO/EB and DAPI staining showed nuclear fragmentation, blebbing and condensation in MCF-7 cells following BBAP-7 treatment. The red-to-green intensity ratio of JC-1 stained MCF-7 cells decreased after BBAP-7 treatment, indicating mitochondrial-mediated apoptosis. DMBA caused mammary gland dysplasia, duct hyperplasia and ductal carcinoma in situ. Carmine staining, histopathology, and scanning electron microscopy demonstrated that BBAP-7, alone or with tirapazamine, restored mammary gland surface morphology and structural integrity. Additionally, BBAP-7 therapy significantly reduced oxidative stress and glycolysis. The findings reveal that BBAP-7 activates PHD-2, making it a promising anticancer drug.
Insights
This study identified BBAP-7 as a novel prolyl hydroxylase-2 (PHD-2) activator. BBAP-7 demonstrates anticancer properties by inducing apoptosis and restoring mammary gland structure, offering a promising new cancer therapy.
Area of Science:
- Oncology
- Molecular Biology
- Drug Discovery
Background:
- Normoxic inactivation of prolyl hydroxylase-2 (PHD-2) promotes tumor growth via HIF-1α and NF-κB.
- Targeting PHD-2 is a potential strategy for cancer therapy.
Purpose of the Study:
- To identify small molecule activators of PHD-2.
- To evaluate the anticancer efficacy of identified PHD-2 activators.
Main Methods:
- Virtual screening of 265,242 compounds for furan chalcone scaffold similarity.
- In vitro PHD-2 activation assay (2-oxoglutarate assay).
- Cytotoxicity and apoptosis assays (MTT, DAPI, JC-1, AO/EB) on MCF-7 cells.
- In vivo antineoplastic efficacy study using a DMBA-induced mammary gland cancer model.
Main Results:
- BBAP-7 identified as a potent PHD-2 activator.
- BBAP-7 exhibits significant cytotoxicity against MCF-7 cells (IC50 = 18.84 µM) and induces apoptosis.
- In vivo studies show BBAP-7 restores mammary gland morphology, reduces oxidative stress, and glycolysis.
Conclusions:
- BBAP-7 is a validated PHD-2 activator with promising anticancer properties.
- BBAP-7 demonstrates therapeutic potential for mammary gland cancer by targeting key oncogenic pathways.
More Related Videos
13:38Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
Published on: January 18, 2017
12:57X-Ray Visualization of Intraductal Ethanol-Based Ablative Treatment for Prevention of Breast Cancer in Rat Models
Published on: December 9, 2022